Views & Analysis Infographic: Solving the challenges of immuno-oncology trial... The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.
News Novartis sheds MorphoSys staff, sites after pelabresib delay Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
